
A Randomized, Double-Blind, Head-to-Head Phase 3 Trial to Evaluate the Efficacy and Safety of LYT-100 (Deupirfenidone) Compared to Pirfenidone at 52 Weeks in Adults With Idiopathic Pulmonary Fibrosis (SURPASS-IPF)
Short Title: Surpass
Enrollment Status: Recruiting
NCT #: NCT07284602
Specialty Area: Pulmonology
Condition Studied: Idiopathic Pulmonary Fibrosis (IPF)
Age Groups: Adult; Older Adult
Phase: III
Study Information
Summary / Purpose
The purpose of this study is to look at how well deupirfenidone improves lung function and how safe it is for people with idiopathic pulmonary fibrosis (IPF) when compared with pirfenidone.
Study Type: Interventional
Accepts Healthy Volunteers: No
Who Can Participate
Eligibility Criteria:
- Adults 40+ years of age
- Diagnosed with idiopathic pulmonary fibrosis (IPF) within the past 7 years
- Willing to follow study contraception requirements
- Limited prior treatment with certain approved IPF medications and not currently receiving background antifibrotic therapy
- Lung function (FVC) of at least 45% predicted
What's Involved
Participation in the study will include:
- Taking the study medication by mouth three times a day
- Completing breathing tests to measure lung function• Undergoing lung imaging with high-resolution CT (HRCT) scans
- Having heart monitoring tests (ECGs)
- Providing blood and urine samples for safety monitoring
- Completing questionnaires about your symptoms, daily activities, and quality of life
- Attending regular study visits and health assessments
Principal Investigator

Additional Information
Location: Renown Health, Office of Clinical Research
Address: 1500 E 2nd St. Reno, NV 89502
General Research: 775-982-3646
Oncology Research: 775-982-5050
Email: Renown-CRD@renown.org
Address: 1500 E 2nd St. Reno, NV 89502
General Research: 775-982-3646
Oncology Research: 775-982-5050
Email: Renown-CRD@renown.org
Complete Study Details: https://clinicaltrials.gov/study/NCT07284602
Disclaimer: This listing gives you general information about the study and isn't part of the official consent process. If you decide to learn more, the research team will talk with you and check if you meet any additional requirements to join the study.